Request a Proposal  
John W Colby III

By: John W Colby III on August 13th, 2019

Print/Save as PDF

Importance of Natural History Studies to Rare Disease Drug Development

Rare & Orphan Disease

When working on a rare disease program, there are far reaching benefits to conducting a natural history (NH) study. In this article, Pharm-Olam's Dr. Jovana Vlajkovic-Josic was interviewed by Melissa Fassbender from Outsourcing-Pharma.

Read the full version of Natural history studies 'essential' for rare disease drug development.

Read More

About Pharm-Olam as a Rare Disease CRO

Pharm-Olam is Helping Create a Healthier World as a global, mid-sized CRO offering flexible, innovative, and highly personalized clinical solutions to pharmaceutical, biotechnology, and life science companies. We have conducted over 100 rare disease studies.  To learn more about our rare disease expertise, visit our Rare Disease Center of Excellence service page.  

About John W Colby III

John is the head of marketing at Pharm-Olam, and has had the opportunity to see the industry from different perspectives over his 15 years; from proposals to sales, to operations and partnership oversight, to corporate strategy and marketing. When not on the job, you will probably find John out on the hiking trails with his wife and four young boys, enjoying the great outdoors.